ArticleProceedings of the National Academy of Sciences of the United States of America2026

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer.

Nicole A Traphagen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.